CYP2C19 and transient ischemic attack: This prespecified subgroup analysis of the randomized clinical CHANCE-2 trial investigates whether the efficacy and safety of ticagrelor-aspirin vs clopidogrel-aspirin are consistent with the expected degree of CYP2C19 loss-of-function after transient ischemic attack or minor stroke.